These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36583245)

  • 1. Unequal allocation of sample/event sizes with considerations of sampling cost for testing equality, non-inferiority/superiority, and equivalence of two Poisson rates.
    Luh WM; Guo JH
    Int J Biostat; 2024 May; 20(1):143-156. PubMed ID: 36583245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing two variances for superiority/non-inferiority and equivalence: Using the exhaustion algorithm for sample size allocation with cost.
    Guo JH; Luh WM
    Br J Math Stat Psychol; 2020 May; 73(2):316-332. PubMed ID: 31190402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size planning with the cost constraint for testing superiority and equivalence of two independent groups.
    Guo JH; Chen HJ; Luh WM
    Br J Math Stat Psychol; 2011 Nov; 64(3):439-61. PubMed ID: 20704777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size planning for the noninferiority or equivalence of a linear contrast with cost considerations.
    Luh WM; Guo JH
    Psychol Methods; 2016 Mar; 21(1):13-34. PubMed ID: 26121080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation.
    Quartagno M; Walker AS; Babiker AG; Turner RM; Parmar MKB; Copas A; White IR
    Trials; 2020 Feb; 21(1):145. PubMed ID: 32029000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial.
    Solaymani-Dodaran M; Basiri P; Moradi M; Gohari K; Sheidaei A; Ahi M; Ghafoori Naeeni F; Ansarifar A; Rahimi Z; Gholami F; Karimi Rahjerdi A; Hamidi Farahani R; Naderi Saffar K; Ghasemi S; Shooshtari A; Honari M; Mozafari A; Khodaverdloo S; Forooghizadeh M
    Virol J; 2023 Jul; 20(1):154. PubMed ID: 37464440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing the equality of two Poisson means using the rate ratio.
    Ng HK; Tang ML
    Stat Med; 2005 Mar; 24(6):955-65. PubMed ID: 15532090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using information from network meta-analyses to optimize the power and sample allocation of a subsequent trial with a new treatment.
    Hu D; Wang C; Ye F; O'Connor AM
    BMC Med Res Methodol; 2022 Nov; 22(1):299. PubMed ID: 36418960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wald tests for variance-adjusted equivalence assessment with normal endpoints.
    Chen YM; Weng YT; Dong X; Tsong Y
    J Biopharm Stat; 2017; 27(2):308-316. PubMed ID: 27906607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When inferiority meets non-inferiority: implications for interim analyses.
    Bratton DJ; Williams HC; Kahan BC; Phillips PP; Nunn AJ
    Clin Trials; 2012 Oct; 9(5):605-9. PubMed ID: 22796636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A more efficient three-arm non-inferiority test based on pooled estimators of the homogeneous variance.
    Lu H; Jin H; Zeng W
    Stat Methods Med Res; 2018 Aug; 27(8):2437-2446. PubMed ID: 27920362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size for comparing negative binomial rates in noninferiority and equivalence trials with unequal follow-up times.
    Tang Y
    J Biopharm Stat; 2018; 28(3):475-491. PubMed ID: 28541744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
    Lui KJ; Chang KC
    Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choosing and changing the analysis scale in non-inferiority trials with a binary outcome.
    Li Z; Quartagno M; Böhringer S; van Geloven N
    Clin Trials; 2022 Feb; 19(1):14-21. PubMed ID: 34693789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.